Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3332012 | Hematology/Oncology Clinics of North America | 2009 | 18 Pages |
Abstract
Gastrointestinal stromal tumor (GIST) is a rare neoplasm that recently has become an intense focus of scientific investigation, as it serves as a model for the molecular therapy for cancer. Although surgery remains the principle treatment of primary localized GIST, imatinib mesylate, a selective inhibitor of KIT protein, achieves dramatic responses in metastatic GIST. Multimodality therapy integrating surgery and molecular therapy has shown promise. This article summarizes the epidemiology, clinicopathologic features, natural history, and clinical management of GIST.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Umer I. Chaudhry, Ronald P. DeMatteo,